Sign up to access all valuation multiples
Nanosonics is a single-product firm and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics’ revenue is made up of capital sales of Trophon units, ongoing consumables sales, and service revenue. By June 2022, there were 29,850 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, about 44% in the US to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
2000
470
LTM Revenue $130M
LTM EBITDA $16.8M
$738M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanosonics has a last 12-month revenue (LTM) of $130M and a last 12-month EBITDA of $16.8M.
In the most recent fiscal year, Nanosonics achieved revenue of $128M and an EBITDA of $20.4M.
Nanosonics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanosonics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $130M | XXX | $128M | XXX | XXX | XXX |
| Gross Profit | $102M | XXX | $100M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $16.8M | XXX | $20.4M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $11.4M | XXX | $5.7M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $13.3M | XXX | $13.3M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 3, 2025, Nanosonics's stock price is AUD 4 (or $3).
Nanosonics has current market cap of AUD 1.3B (or $837M), and EV of AUD 1.1B (or $738M).
See Nanosonics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $738M | $837M | XXX | XXX | XXX | XXX | $0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 3, 2025, Nanosonics has market cap of $837M and EV of $738M.
Nanosonics's trades at 6.2x EV/Revenue multiple, and 42.9x EV/EBITDA.
Equity research analysts estimate Nanosonics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanosonics has a P/E ratio of 63.1x.
See valuation multiples for Nanosonics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $837M | XXX | $837M | XXX | XXX | XXX |
| EV (current) | $738M | XXX | $738M | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 43.9x | XXX | 42.9x | XXX | XXX | XXX |
| EV/EBIT | 64.5x | XXX | 237.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 63.1x | XXX | 77.4x | XXX | XXX | XXX |
| EV/FCF | 37.4x | XXX | 41.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanosonics's last 12 month revenue growth is 10%
Nanosonics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Nanosonics's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanosonics's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanosonics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanosonics acquired XXX companies to date.
Last acquisition by Nanosonics was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanosonics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Nanosonics founded? | Nanosonics was founded in 2000. |
| Where is Nanosonics headquartered? | Nanosonics is headquartered in Australia. |
| How many employees does Nanosonics have? | As of today, Nanosonics has 470 employees. |
| Who is the CEO of Nanosonics? | Nanosonics's CEO is Mr. Michael Kavanagh. |
| Is Nanosonics publicy listed? | Yes, Nanosonics is a public company listed on ASX. |
| What is the stock symbol of Nanosonics? | Nanosonics trades under NAN ticker. |
| When did Nanosonics go public? | Nanosonics went public in 2007. |
| Who are competitors of Nanosonics? | Similar companies to Nanosonics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Nanosonics? | Nanosonics's current market cap is $837M |
| What is the current revenue of Nanosonics? | Nanosonics's last 12 months revenue is $130M. |
| What is the current revenue growth of Nanosonics? | Nanosonics revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Nanosonics? | Current revenue multiple of Nanosonics is 5.7x. |
| Is Nanosonics profitable? | Yes, Nanosonics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nanosonics? | Nanosonics's last 12 months EBITDA is $16.8M. |
| What is Nanosonics's EBITDA margin? | Nanosonics's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Nanosonics? | Current EBITDA multiple of Nanosonics is 43.9x. |
| What is the current FCF of Nanosonics? | Nanosonics's last 12 months FCF is $19.7M. |
| What is Nanosonics's FCF margin? | Nanosonics's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Nanosonics? | Current FCF multiple of Nanosonics is 37.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
